Skip to NavigationSkip to content

Seattle Genetics reports topline phase 3 HER2-Positive Breast Cancer Data

Published on 25/10/19 at 10:24am

Seattle Genetics, a strong competitor in the breast cancer space, has reported topline results in its phase 3 study evaluating tucatinib as an adjunctive therapy to Roche’s Herceptin (trastuzumab) plus capecitabine against Herceptin and capecitabine in third-line HER2- positive breast cancer patients.

Commenting on the results analyst Andrew Fein, said: “We are impressed by the remarkable survival benefits in the overall patient population, with a 46% risk reduction of disease progression or death (p<0.00001), as well as a 34% risk reduction of death (p=0.0048)."

“The results were even greater among patients with brain metastasis; 52% showed reduction of risk for disease progression or passed away (p<0.00001).”

Fein illustrated that the differentiating value of tucatinib suggests a strong commercial outlook in the competitive HER2+ breast cancer landscape particularly in the subpopulation of patients with brain metastasis, where there is a significant unmet need.

Unlike antibody based treatments, tucatinib penetrates the brain making it ideal as a complement to those therapies rather than a specific competitor.

Additionally tucatinib does not bind to the EGFR receptor and as consequence has a much better safety profile.

The new data invoked a 15% spike in Seattle Genetics share price as the drug has the potential to sponge onto the massive success of Roche’s HER2 franchise which achieved sales of almost $7bn last year after feeling the effects of biosimilar competition.

Seattle Genetics licensed tucatinib from Cascadian Therapeutics last year in a deal that was valued at $614 million and it seems the deal was intrinsically valuable on the face of this new data.

One potential concern is the safety profile in the HER2CLIMB study with around 5% of patients taking the drug showing an increase in two enzymes that point to liver damage as compared to a control which saw only a 0.5% increase.

Nik Kiran

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches